Crossmark

Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma

Crossref DOI link: https://doi.org/10.1007/s12672-025-02397-3

Published Online: 2025-05-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Qingyu

Wang, Chendong

You, Ran

Leng, Bin

Yu, Zeyu

Lu, Ya

Diao, Lingfeng

Jiang, Hao

Wu, Bei

Yin, Guowen
Funding

Funding for this research was provided by:

Development of Young Professional Technical Talent in Jiangsu Cancer Hospital (2017YQL-12)
License Information

Text and Data Mining valid from 2025-05-16

Version of Record valid from 2025-05-16
More Information

Article History

Received: 23 December 2024

Accepted: 15 April 2025

First Online: 16 May 2025

Declarations

:

: The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments and was approved by the Ethics Committee of Jiangsu Cancer Hospital.

: The consents from participants were waived in this retrospective study, which was approved by our ethics committee (KY-2024-083).

: The author reports no conflicts of interest in this work.

Document is current

Any future updates will be listed below